Ki-67 Levels and Their Association With Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Prospective Observational Study

This study investigated the association between Ki-67 expression and response to neoadjuvant chemotherapy (NACT) with a docetaxel-carboplatin (DC) regimen in 23 patients with triple-negative breast cancer (TNBC). The mean Ki-67 level was 36%, but it showed no significant correlation with age, menopausal status, tumor size, nodal status, or grade. The complete clinical, imaging, and pathological response rates to the DC regimen were 39.13%, 34.78%, and 47.61%, respectively. Common side effects included malaise, nausea, and hair loss, but no severe side effects were reported. During follow-up, 20 patients showed no local recurrence or metastasis. Overall, Ki-67 levels were not significantly associated with treatment response.